Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F.

Leuk Lymphoma. 2014 Aug;55(8):1925-9. doi: 10.3109/10428194.2013.855309. Epub 2014 Feb 4. No abstract available.

2.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M.

Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Review. Erratum in: Leukemia. 2015 Feb;29(2):516.

3.

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G.

Leukemia. 2012 May;26(5):1106-7. doi: 10.1038/leu.2011.342. Epub 2011 Nov 29. No abstract available.

4.

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.

Berenstein R, Blau IW, Kar A, Cay R, Sindram A, Seide C, Blau O.

J Exp Clin Cancer Res. 2014 May 21;33:44. doi: 10.1186/1756-9966-33-44.

5.

GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.

Perugini M, Iarossi DG, Kok CH, Cummings N, Diakiw SM, Brown AL, Danner S, Bardy P, Bik To L, Wei AH, Lewis ID, D'Andrea RJ.

Leukemia. 2013 Jul;27(7):1588-92. doi: 10.1038/leu.2012.346. Epub 2012 Nov 28. No abstract available.

PMID:
23187294
6.

Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.

Emadi A, Faramand R, Carter-Cooper B, Tolu S, Ford LA, Lapidus RG, Wetzler M, Wang ES, Etemadi A, Griffiths EA.

Am J Hematol. 2015 May;90(5):E77-9. doi: 10.1002/ajh.23965. Epub 2015 Feb 27.

7.

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.

Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2011 Aug;57(2):204-9. doi: 10.1002/pbc.23179. Epub 2011 Apr 18.

8.

Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.

Gorniak P, Ejduk A, Borg K, Makuch-Lasica H, Nowak G, Lech-Maranda E, Prochorec-Sobieszek M, Warzocha K, Juszczynski P.

Eur J Haematol. 2016 Feb;96(2):181-7. doi: 10.1111/ejh.12566. Epub 2015 May 13.

PMID:
25891904
9.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
10.

[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].

Shang Z, Wang D, Xiao M, Wang J, Li TJ, Zhao YC, Li CR, Zhou JF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):607-12. doi: 10.7534/j.issn.1009-2137.2013.03.014. Chinese.

PMID:
23815907
11.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
12.

Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations.

Benton CB, Ravandi F, Andreeff M, Kadia T, Ruvolo V, Qiu P, Wheeler DA, Garcia-Manero G, Cortes J, Kantarjian HM, Konopleva M.

Leuk Lymphoma. 2014 Jun;55(6):1431-4. doi: 10.3109/10428194.2013.840777. Epub 2013 Nov 1. No abstract available.

13.

IDH mutations in acute myeloid leukemia.

Rakheja D, Konoplev S, Medeiros LJ, Chen W.

Hum Pathol. 2012 Oct;43(10):1541-51. doi: 10.1016/j.humpath.2012.05.003. Epub 2012 Aug 20. Review.

PMID:
22917530
14.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

15.

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.

Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J, Adam E, Kozma A, Orban TI, Lovas N, Sipos A, Karaszi E, Dolgos J, Fekete S, Reichardt J, Lehoczky E, Masszi T, Tordai A, Andrikovics H.

Leuk Lymphoma. 2013 May;54(5):1028-35. doi: 10.3109/10428194.2012.736981. Epub 2012 Nov 6.

PMID:
23039322
17.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.

18.

Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?

Zebisch A, Hoefler G, Quehenberger F, Wölfler A, Sill H.

Leukemia. 2013 Aug;27(8):1777-8. doi: 10.1038/leu.2013.48. Epub 2013 Feb 18. No abstract available.

PMID:
23417030
19.

Deep Sequencing of Acute Myeloid Leukemia Reveals Driver Mutations and New Targets.

Brower V.

J Natl Cancer Inst. 2016 Feb 9;108(2). pii: djw018. doi: 10.1093/jnci/djw018. Print 2016 Feb. No abstract available.

PMID:
26864927
20.

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.

Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Ann Hematol. 2017 Apr;96(4):559-565. doi: 10.1007/s00277-016-2912-7. Epub 2017 Jan 5.

PMID:
28058491

Supplemental Content

Support Center